ABSTRACT
Objective To observe the efifcacy and safety of XELOX plus bevacizumab as a ifrst-ine treatment for Chinese patients with metastatic colorectal cancer. Methods In this study, we retrospectively reviewed cases in which XELOX plus bevacizumab were administered in order to evaluate its efifcacy and safety in clinical practice.In total, 40 patients with mCRC who presented at Fuchu Hospital received XELOX plus bevacizumab as a ifrst?line treatment from September, 2009 to April, 2012. Eligible patients had histologically conifrmed mCRC. XELOX consisted of a 2-h intravenous infusion of oxaliplatin 130 mg/m 2 on day 1 plus oral capecitabine 1,000 mg/m 2 twice daily for two weeks of athree?week cycle. Overall survival (OS) and survival benefit were analyzed when patients continued with XELOX plus bevacizumab beyond disease progression. Results The median progression?free survival (PFS) was 290 days [95%conif-dence interval (CI):222?409 days] and the median OS was 816 days (95%CI:490?842 days). The response rate (RR:complete plus partial response) was 67.5%, and the disease control rate (RR plus stable disease) was 90%. Conclusion XELOX plus bevacizumab may be considered a routine ifrst?line treatment option for patients with mCRC.
ABSTRACT
@#目的观察带锁髓内钉固定结合自体骨髓移植治疗长管状骨骨折和骨折不愈合的疗效。方法对12例股骨、胫骨长管状骨骨折和骨折不愈合患者行带锁髓内钉固定、复位,同时行自体骨髓移植治疗(每2周移植1次,共移植3—6次)。结果所有病例均未出现骨折延迟愈合或不愈合,于10—18个月时取出髓内钉,未出现断钉、关节功能障碍、骨密度明显降低等。结论带锁髓内钉固定结合自体骨髓移植是一种可行的治疗长管状骨骨折与骨折不愈合的有效方法。
ABSTRACT
Objective To develop a cutting and coagulation device with searching for surgical operation method. Methods By using the relative theory of electric technology, choice some ceramics matter and form any vibration frequency and carry out cutting biology organization and stopping blood. Results The sample instrument was made successfully, and was used in the animal experiments and clinical experiments. Conclusion This instrument has much better applying prospect and greater market demand.